SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hommes, O R
Right arrow Articles by Weiner, H L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hommes, O R
Right arrow Articles by Weiner, H L
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Results of an international questionnaire on immunosuppressive treatment of multiple sclerosis

O R Hommes

European Charcot Foundation, Heiweg 97, Nijmegen 6533 PA, The Netherlands, info{at}charcot-ms.org

H L Weiner

Multiple Sclerosis Center, Brigham and Women's/Massachusetts General Hospitals, Center for Neurologic Diseases, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA

In November 2000, a questionnaire was sent to 702 multiple sclerosis (MS) centers. Data on the institute, treating neurologists, number of MS patients under care, and the number of patients treated with immunosuppressive treatments were collected. The results indicate that overall, around 10% of MS patients are treated with one of four drugs: azathioprine, cyclophosphamide, methotrexate, and mitoxantrone. Azathioprine was most frequently used. More than 30% of MS patients in France are treated with immunosuppressive drugs. In some other countries, these treatments are hardly prescribed.

Key Words: azathioprine • cyclophosphamide • immunosuppressive treatments • methotrexate • mitoxantrone • questionnaire

Multiple Sclerosis, Vol. 8, No. 2, 139-141 (2002)
DOI: 10.1191/1352458502ms791oa
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Mult SclerHome page
C. Lebrun, M. Debouverie, P. Vermersch, P. Clavelou, L. Rumbach, J. de Seze, S. Wiertlevski, G. Defer, O. Gout, F. Berthier, et al.
Cancer risk and impact of disease-modifying treatments in patients with multiple sclerosis
Multiple Sclerosis, April 1, 2008; 14(3): 399 - 405.
[Abstract] [PDF]

Home page
 Mult SclerHome page
C Lebrun, H Alchaar, M Candito, V Bourg, and M Chatel
Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue
Multiple Sclerosis, June 1, 2006; 12(3): 321 - 324.
[Abstract] [PDF]

Home page
 Mult SclerHome page
D R Smith, B Weinstock-Guttman, J A Cohen, X Wei, C Gutmann, R Bakshi, M Olek, L Stone, S Greenberg, D Stuart, et al.
A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta
Multiple Sclerosis, October 1, 2005; 11(5): 573 - 582.
[Abstract] [PDF]


Advertisement